window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

SBTi

  • Biotech & Pharma Business,Manufacturing & Supply Chain,Research & Development

    Piramal Pharma reports 22.6% emissions reduction and zero OAI observations in sustainability report

    Piramal Pharma has reported a 22.6% reduction in Scope 1 [...]

    August 26, 2026
  • Biotech & Pharma Business,Manufacturing & Supply Chain

    SGD Pharma reports emissions reduction and sustainable packaging progress

    SGD Pharma has reported a 27% reduction in Scope 1 [...]

    July 9, 2026
  • Drug Discovery & Development,Manufacturing & Supply Chain

    Sharp’s climate targets validated by SBTi as company commits to 90% emissions reduction by 2050

    Packaging and clinical trial services provider Sharp strengthens its climate [...]

    May 5, 2026
  • Manufacturing & Supply Chain

    Symbiosis earns recognition from EcoVadis for commitment to sustainability

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Sapience Therapeutics gets FDA clearance for ST316 FAP study
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • EURneffy recommended for emergency anaphylaxis treatment in NHS Wales
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Lifebit awarded three-year NIHR BioResource research environment contract
    Categories: Biotech & Pharma Business, Digital & Data, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top